Development of small molecule epigenetic therapeutics for prostate cancer

前列腺癌小分子表观遗传学疗法的开发

• 批准号: 10558443
• 负责人: JUNG-MO AHN
• 金额: $ 5.5万
• 依托单位: RAPHAEL PHARMACEUTICALS LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10558443
• 关键词: Address; Administrative Supplement; Biotechnology; Businesses; Client; Clinical; Development; Disease; Disease Progression; Drug resistance; Epigenetic Process; Future; Grant; Industry; Innovation Corps; Interview; Knowledge; Lead; Learning; Legal patent; Malignant Neoplasms; Malignant neoplasm of prostate; Medical center; Metastatic Prostate Cancer; Metastatic/Recurrent; Modeling; Nuclear Hormone Receptors; Pathway interactions; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Postdoctoral Fellow; Prevalence; Prostate Cancer therapy; Public Health; Research; Scientist; Seasons; Small Business Technology Transfer Research; Technology; Therapeutic; Time; Training; Training Programs; Transcriptional Regulation; Work; analog; base; castration resistant prostate cancer; commercialization; design; effective therapy; high risk; inhibitor; meetings; member; men; product development; programs; prostate cancer progression; prostate carcinogenesis; small molecule; success

In this administrative supplement proposal, we form a three-team member to participate I-Corps program. Our team consists of Dr. Zhi-Ping Liu (C-level corporate officer), Dr. Qing-Jun Zhang (Technical Lead), and Mr. Kellen Ragsdale (Industry Expert). Dr. Liu is the scientific co-founder of Raphael Pharmaceuticals LLC, the grantee small business. Dr. Liu’s lab established KDM4B as a target for prostate tumorigenesis and identified lead compounds B3 and its analogs. She is one of the inventors of our technology, use of KDM4B inhibitors in prostate cancer therapy, and PI of the STTR Phase I grant. Dr. Liu will lead the three-member team and implement the overall commercialization strategy for the project based on knowledge gained during the I-Corps program. Dr. Zhang has been trained as post-doc with Dr. Liu and is now a senior research scientist in her lab and Technical lead in Raphael Pharmaceuticals. Dr. Zhang has scientific background in epigenetics, nuclear hormone receptors, cancer, and transcriptional regulation. His expertise and work in epigenetics contributed significantly to our project development. Dr. Zhang has participated in all aspects of the development of KDM4B inhibitors in Dr. Liu’s lab and is intimately familiar with the technology. Mr. Ragsdale was a Business Development Manager at UT Southwestern Medical Center. He is a recognized expert in commercializing MedTech and BioTech products and seasoned independent consultant who helps his clients with their IP needs in all aspects of early- stage technology, product development, and business creation. Mr. Ragsdale had extensive meetings with the technology inventor Dr. Zhi-Ping Liu on the project and is very enthusiastic and committed to the project. All team members are committed to the program and able to meet the time-intensive requirements of the training program. Our technology has been filed for patent protection. The aim of the proposal is to learn from the I-Corps program how to conduct background research into competitive IP landscape, value proposition, market assessment, reimbursement model, and identifying commercialization pathway. We are willing to modify, realign, and pivoting our initial commercialization strategy based on thorough interview with potential customers and industry experts and knowledge gained from the program.

在这份行政补充提案中，我们组成了一个三人小组来参加I-Corps计划。我们 团队成员包括刘志平博士（公司C级官员）、张庆军博士（技术负责人）和Kellen先生 Ragsdale（行业专家）。刘博士是Raphael Pharmaceuticals LLC的科学联合创始人， 小生意。刘博士的实验室将KDM 4 B确定为前列腺肿瘤发生的靶点，并确定了铅 化合物B3及其类似物。她是我们技术的发明者之一，在前列腺中使用KDM 4 B抑制剂 癌症治疗，以及STTR I期补助金的PI。刘博士将领导三人小组， 根据I-Corps计划期间获得的知识，制定项目的总体商业化战略。博士 张博士曾在刘博士手下接受博士后培训，现在是她实验室的高级研究科学家， 拉斐尔制药的首席执行官张博士拥有表观遗传学、核激素 受体、癌症和转录调控。他在表观遗传学方面的专业知识和工作做出了重大贡献 我们的项目开发。Zhang博士参与了KDM 4 B抑制剂开发的各个方面 他在刘博士的实验室工作，对这项技术非常熟悉。Ragsdale先生是一名业务发展经理 在UT西南医学中心他是公认的医学技术和生物技术商业化专家 产品和经验丰富的独立顾问谁帮助他的客户与他们的知识产权需求在各个方面的早期- 阶段技术、产品开发和业务创建。Ragsdale先生与 技术发明人刘治平博士对该项目非常热情，并致力于该项目。所有 团队成员致力于该计划，并能够满足培训的时间密集型要求 程序.我们的技术已申请专利保护。该提案的目的是向I军团学习 计划如何对竞争性知识产权格局，价值主张，市场进行背景研究 评估、补偿模式和确定商业化途径。我们愿意修改， 根据与潜在客户的全面访谈，重新调整和调整我们最初的商业化战略 和行业专家以及从该计划中获得的知识。